Literature DB >> 19343511

The epidemiology of triple-negative breast cancer, including race.

Katrina F Trivers1, Mary Jo Lund, Peggy L Porter, Jonathan M Liff, Elaine W Flagg, Ralph J Coates, J William Eley.   

Abstract

OBJECTIVE: Predictors of intrinsic breast cancer subtypes, including the triple-negative (TN) subtype, are largely unknown. We evaluated whether anthropometrics, demographics, and reproductive history were associated with distinct breast cancer subtypes.
METHODS: Invasive breast tumors from a population-based case-control study of 476 (116 black and 360 white) Atlanta women aged 20-54, diagnosed between 1990 and 1992, were centrally reviewed and immunohistochemically analyzed for estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2); then grouped [TN (ER-PR-HER2-); ER-PR-HER2+; ER/PR+HER2+; ER/PR+HER2- (case-only reference group)]. Data were from interviews and anthropometric measurements; adjusted odds ratios (OR) and 95% confidence intervals (CI) were estimated using logistic regression, including both case-only and case-control comparisons.
RESULTS: From the case-only analyses and compared with the ER/PR+HER2- subtype, women with TN tumors were more likely to be obese than normal/underweight [OR = 1.89 (95% CI = 1.22, 2.92)]. Regardless of HER2 status, ER-PR- tumors were associated with black race, young age at first birth, having a recent birth, and being overweight.
CONCLUSIONS: Distinct breast cancer subtypes have unique sociodemographic, anthropometric and reproductive characteristics and possibly different pathways for development.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19343511      PMCID: PMC4852686          DOI: 10.1007/s10552-009-9331-1

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  45 in total

1.  Immunohistological demonstration of progesterone receptor in breast carcinomas: correlation with radioligand binding assays and oestrogen receptor immunohistology.

Authors:  D D Giri; J R Goepel; K Rogers; J C Underwood
Journal:  J Clin Pathol       Date:  1988-04       Impact factor: 3.411

2.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

3.  Statistical analysis of molecular epidemiology studies employing case-series.

Authors:  C B Begg; Z F Zhang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1994-03       Impact factor: 4.254

4.  Advanced stages and poorly differentiated grade are associated with an increased risk of HER2/neu positive breast carcinoma only in White women: findings from a prospective cohort study of African-American and White-American women.

Authors:  Azadeh Stark; Alissa Kapke; Daniel Schultz; Ron Brown; Michael Linden; Usha Raju
Journal:  Breast Cancer Res Treat       Date:  2007-04-13       Impact factor: 4.872

5.  Body mass and mortality after breast cancer diagnosis.

Authors:  Maura K Whiteman; Susan D Hillis; Kathryn M Curtis; Jill A McDonald; Phyllis A Wingo; Polly A Marchbanks
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-08       Impact factor: 4.254

6.  Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women.

Authors:  Amanda I Phipps; Kathleen E Malone; Peggy L Porter; Janet R Daling; Christopher I Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-07-29       Impact factor: 4.254

7.  Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections.

Authors:  G Cattoretti; M H Becker; G Key; M Duchrow; C Schlüter; J Galle; J Gerdes
Journal:  J Pathol       Date:  1992-12       Impact factor: 7.996

8.  Oral contraceptives and breast cancer risk among younger women.

Authors:  L A Brinton; J R Daling; J M Liff; J B Schoenberg; K E Malone; J L Stanford; R J Coates; M D Gammon; L Hanson; R N Hoover
Journal:  J Natl Cancer Inst       Date:  1995-06-07       Impact factor: 13.506

9.  Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer.

Authors:  Amanda I Phipps; Kathleen E Malone; Peggy L Porter; Janet R Daling; Christopher I Li
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

10.  Early onset of breast cancer in a group of British black women.

Authors:  R L Bowen; S W Duffy; D A Ryan; I R Hart; J L Jones
Journal:  Br J Cancer       Date:  2008-01-08       Impact factor: 7.640

View more
  128 in total

Review 1.  Triple-negative breast cancer: present challenges and new perspectives.

Authors:  Franca Podo; Lutgarde M C Buydens; Hadassa Degani; Riet Hilhorst; Edda Klipp; Ingrid S Gribbestad; Sabine Van Huffel; Hanneke W M van Laarhoven; Jan Luts; Daniel Monleon; Geert J Postma; Nicole Schneiderhan-Marra; Filippo Santoro; Hans Wouters; Hege G Russnes; Therese Sørlie; Elda Tagliabue; Anne-Lise Børresen-Dale
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

2.  Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.

Authors:  Christina A Clarke; Theresa H M Keegan; Juan Yang; David J Press; Allison W Kurian; Anish H Patel; James V Lacey
Journal:  J Natl Cancer Inst       Date:  2012-07-05       Impact factor: 13.506

Review 3.  Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti-tumor immunity.

Authors:  Laura M Sipe; Mehdi Chaib; Ajeeth K Pingili; Joseph F Pierre; Liza Makowski
Journal:  Immunol Rev       Date:  2020-05       Impact factor: 12.988

4.  Reproductive history and risk of three breast cancer subtypes defined by three biomarkers.

Authors:  Amanda I Phipps; Diana S M Buist; Kathleen E Malone; William E Barlow; Peggy L Porter; Karla Kerlikowske; Christopher I Li
Journal:  Cancer Causes Control       Date:  2010-12-24       Impact factor: 2.506

5.  Alcohol, smoking, and risk of Her2-overexpressing and triple-negative breast cancer relative to estrogen receptor-positive breast cancer.

Authors:  Michelle L Baglia; Linda S Cook; C Mei-Tzu; Charles Wiggins; Deirdre Hill; Peggy Porter; Christopher I Li
Journal:  Int J Cancer       Date:  2018-07-26       Impact factor: 7.396

Review 6.  Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?

Authors:  Narjust Duma; Kelly C Gast; Grace M Choong; Roberto A Leon-Ferre; Ciara C O'Sullivan
Journal:  Curr Oncol Rep       Date:  2018-06-08       Impact factor: 5.075

Review 7.  Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.

Authors:  Priyanka Sharma
Journal:  Curr Treat Options Oncol       Date:  2018-04-14

Review 8.  Population and target considerations for triple-negative breast cancer clinical trials.

Authors:  Terry Hyslop; Yvonne Michael; Tiffany Avery; Hallgeir Rui
Journal:  Biomark Med       Date:  2013-02       Impact factor: 2.851

9.  Novel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy.

Authors:  Lisa D Volk-Draper; Sandeep Rajput; Kelly L Hall; Andrew Wilber; Sophia Ran
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

10.  Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer.

Authors:  Mariana Chavez-MacGregor; Christina A Clarke; Daphne Y Lichtensztajn; Sharon H Giordano
Journal:  JAMA Oncol       Date:  2016-03       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.